{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T20:06:20Z","timestamp":1778184380173,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008519","name":"University of Arkansas for Medical Sciences Center for Translational Neuroscience","doi-asserted-by":"publisher","award":["GM110702"],"award-info":[{"award-number":["GM110702"]}],"id":[{"id":"10.13039\/100008519","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008519","name":"University of Arkansas for Medical Sciences Translational Research Institute","doi-asserted-by":"publisher","award":["RR029884"],"award-info":[{"award-number":["RR029884"]}],"id":[{"id":"10.13039\/100008519","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institutes of Health National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA039195"],"award-info":[{"award-number":["DA039195"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 DA022981"],"award-info":[{"award-number":["T32 DA022981"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"Intramural Research Programs of the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.neuropharm.2017.09.004","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T18:16:08Z","timestamp":1504635368000},"page":"13-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"PA","title":["Role of monoaminergic systems and ambient temperature in bath salts constituent 3,4-methylenedioxypyrovalerone (MDPV)-elicited hyperthermia and locomotor stimulation in mice"],"prefix":"10.1016","volume":"134","author":[{"given":"Brenda M.","family":"Gannon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenner C.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E.","family":"Fantegrossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.09.004_bib1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.neuropharm.2013.04.003","article-title":"The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats","volume":"71","author":"Aarde","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.004_bib2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/npp.2012.204","article-title":"Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products","volume":"38","author":"Baumann","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.004_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.annemergmed.2012.01.005","article-title":"Hyperthermia and multiorgan failure after abuse of \u2018bath salts\u2019 containing 3,4-methylenedioxypyrovalerone","volume":"60","author":"Borek","year":"2012","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1749-6632.2011.06199.x","article-title":"Designer drugs: a medicinal chemistry perspective","volume":"1248","author":"Carroll","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.116.234252","article-title":"Discriminative stimulus effects of binary drug mixtures: studies with cocaine, MDPV, and caffeine","volume":"359","author":"Collins","year":"2016","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib6","first-page":"65371","article-title":"Schedules of controlled substances: temporary placement of three synthetic cathinones into schedule I. Final order","volume":"76","author":"Drug Enforcement Administration, Department of Justice","year":"2011","journal-title":"Fed. Regist."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib7","first-page":"12938","article-title":"Schedules of controlled substances: temporary placement of 10 synthetic cathinones into schedule I. Final order","volume":"79","author":"Drug Enforcement Administration, Department of Justice","year":"2014","journal-title":"Fed. Regist."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3109\/03009734.2011.563878","article-title":"Assessment of receptor occupancy-over-time of two dopamine transporter inhibitors by [(11)C]CIT and target controlled infusion","volume":"116","author":"Eriksson","year":"2011","journal-title":"Ups. J. Med. Sci."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib9","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.bcp.2013.04.004","article-title":"Substituted methcathinones differ in transporter and receptor interactions","volume":"85","author":"Eshleman","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/npp.2012.233","article-title":"In\u00a0vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity","volume":"38","author":"Fantegrossi","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.004_bib11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00213-005-0005-8","article-title":"Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse","volume":"181","author":"Fantegrossi","year":"2005","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib12","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1007\/s00213-016-4212-2","article-title":"Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders","volume":"233","author":"Ferr\u00e9","year":"2016","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib13","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/BF00207230","article-title":"Pharmacologic specificity of tolerance to caffeine-induced stimulation of locomotor activity","volume":"93","author":"Finn","year":"1987","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib14","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1124\/jpet.103.058206","article-title":"Anxiolytic-like effects of escitalopram, citalopram, and R-citalopram in maternally separated mouse pups","volume":"308","author":"Fish","year":"2004","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1124\/jpet.116.239376","article-title":"Individual differences in the relative reinforcing effects of 3,4-methylenedioxypyrovalerone under fixed and progressive ratio schedules of reinforcement in rats","volume":"361","author":"Gannon","year":"2017","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib16","article-title":"Reinforcing effects of binary mixtures of common bath salts constituents: studies with 3,4-methylenedioxypyrovalerone (MDPV), 3,4-methylenedioxymethcathinone (methylone), and caffeine in rats","author":"Gannon","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.09.004_bib17","doi-asserted-by":"crossref","DOI":"10.1097\/FBP.0000000000000315","article-title":"Reinforcing effects of abused \u201cbath salts\u201d constituents 3,4-methylenedioxypyrovalerone (MDPV) and \u03b1-pyrrolidinopentiophenone (\u03b1-PVP) and their enantiomers","author":"Gannon","year":"2017","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2017.06.031","article-title":"Reinforcing, locomotor, and appetitive stimulus effects of orally self-administered bath salt constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice","author":"Gannon","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib19","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1124\/jpet.115.229500","article-title":"Stereoselective effects of abused \u201cbath salt\u201d constituent 3,4-Methylenedioxypyrovalerone in mice: drug discrimination, locomotor activity, and thermoregulation","volume":"356","author":"Gannon","year":"2016","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/FBP.0b013e328364166d","article-title":"Locomotor stimulant and discriminative stimulus effects of 'bath salt' cathinones","volume":"24","author":"Gatch","year":"2013","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib21","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3109\/15563650.2011.615318","article-title":"Clinical toxicology of newer recreational drugs","volume":"49","author":"Hill","year":"2011","journal-title":"Clin. Toxicol. Phila."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bcpt.12253","article-title":"Mephedrone, methylone and 3,4-methylenedioxypyrovalerone (MDPV) induce conditioned place preference in mice","volume":"115","author":"Karlsson","year":"2014","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib23","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0022-3565(24)37310-0","article-title":"Discriminative stimulus properties of cocaine: enhancement by monoamine reuptake blockers","volume":"284","author":"Kleven","year":"1998","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib24","first-page":"375","article-title":"Illicit bath salts: not for bathing","volume":"52","author":"Kyle","year":"2011","journal-title":"J.\u00a0Miss State Med. Assoc."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF00508342","article-title":"Serotonergic mechanisms in the hypothalamus mediate thermoregulatory responses in rats","volume":"322","author":"Lin","year":"1983","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0022-3565(25)30225-9","article-title":"Postnatal elevation of brain tyrosine hydroxylase activity, without concurrent increases in steady-state catecholamine levels, resulting from dl-alpha-methylparatyrosine administration during embryonic development","volume":"194","author":"Lydiard","year":"1975","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s13181-011-0196-9","article-title":"Death following recreational use of designer drug \u201cbath salts\u201d containing 3,4-Methylenedioxypyrovalerone (MDPV)","volume":"8","author":"Murray","year":"2012","journal-title":"J.\u00a0Med. Toxicol."},{"issue":"5","key":"10.1016\/j.neuropharm.2017.09.004_bib28","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ntt.2012.07.005","article-title":"Disruption of striatal glutamatergic\/GABAergic homeostasis following acute methamphetamine in mice","volume":"34","author":"Pereira","year":"2012","journal-title":"Neurotoxicol. Teratol."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib29","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMc1107097","article-title":"Bath salts\u201d intoxication","volume":"365","author":"Ross","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib30","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00213-015-4057-0","article-title":"Reinforcing and neurochemical effects of the \u201cbath salts\u201d constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats","volume":"233","author":"Schindler","year":"2016","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib31","doi-asserted-by":"crossref","first-page":"e74891","DOI":"10.1371\/journal.pone.0074891","article-title":"Relative contributions of norepinephrine and serotonin transporters to antinociceptive synergy between monoamine reuptake inhibitors and morphine in the rat formalin model","volume":"8","author":"Shen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.09.004_bib32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12640-013-9423-2","article-title":"A\u00a0single neurotoxic dose of methamphetamine induces a long-lasting depressive-like behaviour in mice","volume":"25","author":"Silva","year":"2014","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib33","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1476-5381.2012.02145.x","article-title":"Pharmacological characterization of designer cathinones in\u00a0vitro","volume":"168","author":"Simmler","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib34","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/15563650.2011.590812","article-title":"Clinical experience with and analytical confirmation of \u201cbath salts\u201d and \u201clegal highs\u201d (synthetic cathinones) in the United States","volume":"49","author":"Spiller","year":"2011","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib35","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1471-4159.2007.05155.x","article-title":"The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity","volume":"105","author":"Thomas","year":"2008","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib36","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1590\/1414-431X20143698","article-title":"Effects of acute administration of selective serotonin reuptake inhibitors on sympathetic nerve activity","volume":"47","author":"Tiradentes","year":"2014","journal-title":"Braz J. Med. Biol. Res."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.mp.4000964","article-title":"Cocaine, reward, movement and monoamine transporters","volume":"7","author":"Uhl","year":"2002","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.09.004_bib38","series-title":"World Drug Report 2016","author":"United Nations Office on Drugs and Crime","year":"2016"},{"key":"10.1016\/j.neuropharm.2017.09.004_bib39","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1471-4159.2006.03851.x","article-title":"Differential alpha-mediated inhibition of dopamine and noradrenaline release in the parietal and occipital cortex following noradrenaline transporter blockade","volume":"98","author":"Valentini","year":"2006","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.09.004_bib40","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1369-1600.2012.00474.x","article-title":"Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV)","volume":"19","author":"Watterson","year":"2014","journal-title":"Addict. Biol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817304227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817304227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T15:49:03Z","timestamp":1750866543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817304227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":40,"alternative-id":["S0028390817304227"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.09.004","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of monoaminergic systems and ambient temperature in bath salts constituent 3,4-methylenedioxypyrovalerone (MDPV)-elicited hyperthermia and locomotor stimulation in mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}